MedPath
HSA Approval

ABIRANAT TABLETS 250MG USP

SIN15833P

ABIRANAT TABLETS 250MG USP

ABIRANAT TABLETS 250MG USP

October 18, 2019

NATCO PHARMA ASIA PTE. LTD.

NATCO PHARMA ASIA PTE. LTD.

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantNATCO PHARMA ASIA PTE. LTD.
Licence HolderNATCO PHARMA ASIA PTE. LTD.

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

TABLET

ORAL

Medical Information

L02BX03

abiraterone

Manufacturer Information

NATCO PHARMA ASIA PTE. LTD.

Natco Pharma (Pharma - Division) Limited

Active Ingredients

Abiraterone Acetate

250 mg

Abiraterone

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

ABIRANAT TABLETS 250MG USP - HSA Approval | MedPath